Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes
Brain butyrylcholinesterase (BChE) is an attractive target for drugs designed for the treatment of Alzheimer’s disease (AD) in its advanced stages. It also potentially represents a biomarker for progression of this disease. Based on the crystal structure of previously described highly potent, revers...
| Egile Nagusiak: | , , , , , , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
Taylor & Francis Group
2020-01-01
|
| Saila: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Gaiak: | |
| Sarrera elektronikoa: | http://dx.doi.org/10.1080/14756366.2019.1710502 |